Market Overview:

The global contrast media injectors market reached a value of US$ 1.46 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.16 Billion by 2027, exhibiting a CAGR of 6.30% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Contrast media (CM) injectors are medical devices utilized to inject CM into the body for enhancing the visibility of tissues for different medical imaging procedures. These procedures include computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) or magnetic resonance. CM injectors find extensive applications in radiology, interventional cardiology, ambulatory surgical centers (ASCs), and diagnostic imaging centers across the globe. At present, they have evolved from simple, manual injectors to automated injectors that precisely control the amount of the CM agent used, facilitate automated data collection, and warn about potential hazards, such as air embolisms or extravasations.

Contrast Media Injectors Market Trends:

Increasing preferences for minimally invasive (MI) medical procedures that offer numerous benefits, such as smaller incisions, less postoperative pain, faster recovery, and shorter hospital stay, represents one of the key factors bolstering the growth of the market. Moreover, there is a rise in the use of automated CM injectors in cardiac imaging to help enhance patient safety and improve image quality. Besides this, leading players are focusing on offering personalized CM doses to patients using information from an electronic medical record (EMR) or picture archiving and communication system (PACS). This, coupled with the emergence of syringeless power injectors, which aid in reducing CM waste, is facilitating the growth of the market. Apart from this, there is a widespread prevalence of cancers, including breast, lung, colon, rectum, and prostate cancers, around the world. This, along with the increasing number of regulatory approvals of contrast agents and the significant growth in the healthcare industry, is projected to create a positive outlook for the market in the upcoming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global contrast media injectors market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, injectors type, application and end user.

Breakup by Product Type:

• Consumables

• Syringes
• Tubes
• Others

• Injector Systems

• CT Injectors
• MRI Injectors
• Angiography Injectors
• Accessories
   

Breakup by Injectors Type:

• Single-head Injectors
• Dual-head Injectors
• Syringeless Injectors
   

Breakup by Application:

• Radiology
• Interventional Cardiology
• Interventional Radiology
   

Breakup by End User:

• Hospitals
• Ambulatory Surgery Centers
• Diagnostics Imaging Centers
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being APOLLO RT Co. Ltd., Bayer AG, Bracco Imaging S.p.A., General Electric Company, Guerbet, Medtron AG, Nemoto Kyorindo Co. Ltd., Shenzhen Anke High-tech Co. Ltd., Shenzhen Seacrown Electromechanical Co. Ltd., Sino Medical-Device Technology Co. Ltd. and ulrich GmbH & Co. KG.

Report Coverage: